-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $56

Benzinga·01/09/2026 15:02:01
Listen to the news
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $58 to $56.